HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohn's disease patients

Pharmacogenomics J. 2023 Nov;23(6):141-148. doi: 10.1038/s41397-023-00312-z. Epub 2023 Jul 17.

Abstract

Recently, the HLA-DQA1*05 (rs2097432) genetic variation has been reported to be linked to early infliximab (IFX) treatment failure in the Caucasian Crohn's disease (CD) population, but that evidence is scarce in the Asian population. This study aimed to investigate the relationship between rs2097432 and the cumulative discontinuation-free time of IFX (IFX persistence) in 189 Japanese biologics-naive CD patients. We also performed a genome-wide association study (GWAS) to discover novel genetic predictors for IFX persistence. The C allele of rs2097432 significantly increased the risk of early discontinuation of IFX [Hazard ratio (HR) = 2.23 and P-value = 0.026]. In GWAS, one locus tagged by rs73277969, located upstream of PPARGC1B which attenuates macrophage-mediated inflammation, reached genome-wide significance (HR = 6.04 and P-value = 7.93E-9). Pathway analysis suggested association of signaling by PDGF and FCGR activation signaling with IFX persistence (P-value = 8.56E-5 and 5.80E-4, respectively).

MeSH terms

  • Crohn Disease* / drug therapy
  • Crohn Disease* / genetics
  • East Asian People
  • Gastrointestinal Agents / therapeutic use
  • Genome-Wide Association Study
  • HLA-DQ alpha-Chains* / genetics
  • Humans
  • Infliximab* / therapeutic use
  • RNA-Binding Proteins* / genetics
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Gastrointestinal Agents
  • HLA-DQA1 antigen
  • Infliximab
  • PPARGC1B protein, human
  • RNA-Binding Proteins
  • HLA-DQ alpha-Chains